To validate cancer specificity, performance, and utility as an efficient non-invasive biomarker, the promoter methylation levels of best-performing genes (HOXA9, HIC, and SOX1) were evaluated in matched serum CFDNA samples of patients with EOC. This evidence concerns the gene SOX1 and cancer.